Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and Heron Therapeutics (NASDAQ:HRTX – Get Free Report) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Institutional & Insider Ownership
19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Aspire Biopharma and Heron Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
| Heron Therapeutics | -22.52% | -293.02% | -10.00% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Heron Therapeutics | 1 | 3 | 1 | 0 | 2.00 |
Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 533.91%. Given Heron Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Aspire Biopharma.
Risk & Volatility
Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Valuation and Earnings
This table compares Aspire Biopharma and Heron Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 1,268.40 | -$24.48 million | ($69.62) | -0.13 |
| Heron Therapeutics | $154.90 million | 0.39 | -$20.19 million | ($0.19) | -1.66 |
Heron Therapeutics has higher revenue and earnings than Aspire Biopharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Heron Therapeutics beats Aspire Biopharma on 11 of the 14 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
